Despite rapid advances in medical technology, cancer, dementia, Parkinson's disease, diabetes, and hypertension remain challenges to overcome in an aging society.
Moreover, developing a single global new drug requires an average of more than 10 years and enormous investment costs of over KRW 1 trillion. Despite this, the success rate is extremely low.
To overcome this situation, the 中小企业部 has recently moved to strengthen 新药开发 competitiveness by creating an ecosystem in which large corporations can commercialize 候选物质s developed by domestic 初创企业 ventures. The ministry also plans to further strengthen support for early-stage 初创企业s in the pre-IND candidate discovery phase.
An official from the 韩国毒性研究所, which is promoting this project, stated, "The rewards for success in 新药开发 are enormous, but the possibility of failure is very high, so the key is identifying and supporting pre-初创企业 candidates with technological capabilities," adding, "Prioritized support is needed for pre-candidate and pre-clinical 研发."
RudaCure has gained attention for its independently developed 干眼症治疗药 候选物质. The company is working toward clinical advancement in 韩国 and abroad, with a focus on developing treatments for intractable 感觉障碍 such as 干眼症 and pain.